Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

Trial Profile

A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs SH-229 (Primary) ; Daclatasvir
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Nanjing Sanhome Pharmaceutical
  • Most Recent Events

    • 28 Nov 2018 Planned primary completion date changed from 19 Jan 2019 to 19 Dec 2018.
    • 28 Nov 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 28 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top